Iga Monoclonal Gammopathy of Undetermined Significance

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS research · 2026-04-20
Clinical Trial Update: Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance [Phase 2]
Phase 2 clinical trial evaluating rifaximin versus no intervention for IgA monoclonal gammopathy of undetermined significance; currently rec…